Generate:Biomedicines vs Profluent (2026)
Two generative protein companies at different points on the path from method to medicine. Generate designs therapeutics de novo and has taken assets into clinical development, with a public listing that forced detailed disclosure of the platform and the economics behind it. Profluent came out of the project that first demonstrated language models could generate functional proteins, has been peer reviewed twice at the highest level, and publishes three named access routes from licensing a molecule to platform access. Profluent is the stronger scientific record; Generate is the further along. Neither publishes a release policy or intended use statement, which is the shared gap in a field whose governance question is biosecurity, and neither says what proportion of its designs failed before the ones you hear about.
- It designs protein therapeutics de novo with a model that generates novel structures and sequences, and it has taken assets into clinical development.
- A public listing forced detailed disclosure of the platform, the pipeline and the economics, which is the strongest commercial transparency in this category.
- The generate, test and learn loop runs at industrial scale internally rather than as a partnership dependent process.
- Peer reviewed twice at the highest level, with the foundational demonstration that language models can generate functional proteins published in a major journal.
- Molecular evidence is unusually direct, including designed systems validated experimentally rather than only benchmarked computationally.
- Three access routes are named openly, from licensing a designed molecule through to platform access, which makes the commercial structure legible.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Generate:Biomedicines and Profluent are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Generate:Biomedicines | Profluent |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2018 | 2022 |
| Headquarters | Somerville, MA | Emeryville, CA |
| Website | generatebiomedicines.com | profluent.bio |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Generate:Biomedicines its top capability grade on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Set against Profluent, Generate:Biomedicines grades higher on several axes, including Model Supply Chain Disclosure, Clinical and Operational Evidence and FDA and Regulatory Status. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Profluent its top capability grade on AI Centrality, Model and Technology Transparency and Setting and Specialty Coverage. Set against Generate:Biomedicines, Profluent grades higher on Setting and Specialty Coverage. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Generate:Biomedicines or Profluent?
On the axes where the AI Health Index separates them, Generate:Biomedicines grades higher on several axes, including Model Supply Chain Disclosure, Clinical and Operational Evidence and FDA and Regulatory Status, and Profluent grades higher on Setting and Specialty Coverage. Generate:Biomedicines leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Generate:Biomedicines and Profluent differ most?
The widest separation the AI Health Index records between Generate:Biomedicines and Profluent is on Model Supply Chain Disclosure, where Generate:Biomedicines grades B and Profluent grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Generate:Biomedicines and Profluent grade the same?
The AI Health Index grades Generate:Biomedicines and Profluent the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Neither publishes a governance framework, model card, intended use statement or release policy, which is the notable shared gap given that both design proteins that do not exist in nature and the governance question in this category is biosecurity. Neither holds a located security attestation.
Generate's clinical position is the more advanced, but a clinical stage asset says the platform produced one molecule that reached humans rather than that the platform generalises, and neither company publishes what proportion of its designs failed before that point.